about
Detection of rapalog-mediated therapeutic response in renal cancer xenografts using ⁶⁴Cu-bevacizumab immunoPETPreclinical evaluation of the novel monoclonal antibody H6-11 for prostate cancer imaging.Feasibility of isotope harvesting at a projectile fragmentation facility: ⁶⁷Cu.Evaluation of (89)Zr-pertuzumab in Breast cancer xenografts.Effects of chelator modifications on (68)Ga-labeled [Tyr (3)]octreotide conjugates.Evaluation of hypoxia with copper-labeled diacetyl-bis(N-methylthiosemicarbazone).Investigating the pharmacokinetics and biological distribution of silver-loaded polyphosphoester-based nanoparticles using (111) Ag as a radiotracer.Synthesis and Biological Evaluation of (S)-Amino-2-methyl-4-[(76)Br]bromo-3-(E)-butenoic Acid (BrVAIB) for Brain Tumor Imaging.Assessment of an 18F-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer.Cyclotron Production of High-Specific Activity 55Co and In Vivo Evaluation of the Stability of 55Co Metal-Chelate-Peptide ComplexesImmuno-PET of epithelial ovarian cancer: harnessing the potential of CA125 for non-invasive imagingCross-sections for (p,x) reactions on natural chromium for the production of (52,52m,54)Mn radioisotopes89Zr-Radiolabeled Trastuzumab Imaging in Orthotopic and Metastatic Breast TumorsPET/MRI of Hypoxic Atherosclerosis Using 64Cu-ATSM in a Rabbit Model.The rise of metal radionuclides in medical imaging: copper-64, zirconium-89 and yttrium-86.A historical perspective on the specific activity of radiopharmaceuticals: what have we learned in the 35 years of the ISRC?A historical perspective on the specific activity of radiopharmaceuticals: what have we learned in the 35years of the ISRC?Harvesting (67)Cu from the Collection of a Secondary Beam Cocktail at the National Superconducting Cyclotron Laboratory.Investigation of a vitamin B12 conjugate as a PET imaging probe.Imaging of CD47 expression in xenograft and allograft tumor models.Initial characterization of a dually radiolabeled peptide for simultaneous monitoring of protein targets and enzymatic activity.Imaging of hypoxia in mouse atherosclerotic plaques with (64)Cu-ATSM.[89Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer.Evaluation of Cu-64 and Ga-68 Radiolabeled Glucagon-Like Peptide-1 Receptor Agonists as PET Tracers for Pancreatic β cell Imaging.Development of a Radiolabeled Irreversible Peptide Ligand for PET Imaging of Vascular Endothelial Growth Factor.Cyclotron Production of (99m)Tc using (100)Mo2C targets.Production and separation of (186g)Re from proton bombardment of (186)WC.Long-term evaluation of TiO2-based 68Ge/68Ga generators and optimized automation of [68Ga]DOTATOC radiosynthesis.New Methods for the Site-Selective Placement of Peptides on a Microelectrode Array: Probing VEGF-v107 Binding as Proof of Concept.Calibration setting numbers for dose calibrators for the PET isotopes (52)Mn, (64)Cu, (76)Br, (86)Y, (89)Zr, (124)I.Microfluidic Preparation of a 89Zr-Labeled Trastuzumab Single-Patient Dose.A promising carbon-11-labeled sphingosine-1-phosphate receptor 1-specific PET tracer for imaging vascular injury.Pretargeted Immuno-PET: Overcoming Limitations of Space and Time.Glypican-3-targeted 89Zr PET imaging of hepatocellular carcinoma: where antibody imaging dares to tread.Photonuclear production, chemistry, and in vitro evaluation of the theranostic radionuclide 47Sc.Production cross-sections of 181-186Re isotopes from proton bombardment of natural tungstenCellular and whole-plant chloride dynamics in barley: insights into chloride-nitrogen interactions and salinity responsesA semi-automated system for the routine production of copper-64A new and simple calibration-independent method for measuring the beam energy of a cyclotronSpecific activity measurement of ⁶⁴Cu: a comparison of methods
P50
Q28487987-B73A7573-214C-4A22-B954-9F51B23F681BQ33652622-6935A994-A816-48FF-B2B1-1051343B3EF3Q34375622-45896F20-1982-42C5-B97C-8D193EDAC7D4Q34473478-8941F068-A1C2-4604-9088-D60B1AD627F7Q35087810-4C7B6489-F431-40FE-A15D-25B1513AB3B9Q35116540-A8B886CD-4E60-4DC6-9358-2547A34263D0Q35688572-6440A606-3D7F-451C-B440-59DA73AECB77Q36609872-40BCCD15-B0C7-4D56-A5EF-0AA574FB937DQ36619673-5BD64219-47DA-42BA-BCFD-3B8C77EE7D8CQ36890179-B51FB9B5-2B45-4F45-9583-14B2CCC4052DQ36944360-F6091139-138E-4A92-BDD7-1D848063EF29Q37012499-B442D78B-12EC-4BFD-95E2-9CD5E8CFC881Q37148669-57DAD5A3-5A50-4E21-9846-68145A41E097Q37449411-FFAD5B20-83E3-44B6-9FAE-853E387D4E4AQ37869905-CDF05B50-3FC8-4A30-9309-068A2561F372Q37977229-9B829D3C-6F50-465F-8D22-BF481EAD65D1Q38077319-CC1D3F8F-5CAA-44E5-8DA6-A4DDD124EACAQ38832776-A8B73B27-379D-4D67-BB80-D23ADB1AFBFFQ39002153-6AB3B8CF-1C3F-4929-9A8E-F132BC82CBA7Q39032351-9EBF5699-EF52-42D8-817F-736CDB0C9F02Q39244267-6962A672-788D-49A4-98C3-ED89A9CE9945Q39636702-66CD77C3-8CC3-46F9-A005-4324994B0E35Q39794283-2DA35115-5B01-49B3-A727-BC6FF5F819CEQ40925736-1DD0F669-5025-40C4-9D38-560A99EBCEAAQ44286271-C1EFAC2D-F799-4A9B-AEE9-AAA75D9035B7Q46628066-5F04860A-7C1F-441C-A633-62A3B6BC82E7Q46754310-4178A1C4-30D0-4DAA-997C-FED9256624DDQ47256259-A2A3CB3F-EB9C-46AC-9FB3-317E39D4420AQ51131343-058D6F2C-F6A4-4837-97CD-86C6B5BFC45EQ51342512-51F41E99-7ED2-43D7-8937-A41C5A1B1C0FQ51471788-B03885C7-5EBE-4460-A690-42AF795D1477Q52985195-9F7CCE5D-4949-4494-9811-7934EB3945AFQ52986969-92168E2C-0677-4583-AF71-B768DFC3DD3EQ53073316-02A305D3-E7FA-4693-A410-5226D0BF316DQ64886260-03827E22-FD00-4EFF-AD9B-9D16FC4B5247Q79349426-8E0AF5CD-E1BD-45B1-B323-B198EDB76A6CQ79354662-B71AEEA7-F12A-4FEA-A5F4-474A120434A6Q83933980-FAF10692-7A30-4B15-A505-7B9445DAC877Q85166767-F404EF39-B6CE-4C10-B694-FCFB64A3EC97Q87631025-85B4AC54-9411-4092-952B-D6785EC04F8F
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Suzanne Lapi
@en
Suzanne Lapi
@nl
type
label
Suzanne Lapi
@en
Suzanne Lapi
@nl
altLabel
Lapi S
@en
prefLabel
Suzanne Lapi
@en
Suzanne Lapi
@nl
P31
P496
0000-0003-0090-0191